Gene therapy and gene-editing approvals in selected markets have begun to reshape thalassemia care. But even in the long term, effective oral iron chelation remains central to real-world outcomes - here is why.
1. Where Gene Therapy Stands #
- Beta-globin gene addition (betibeglogene autotemcel) - approved in selected markets
- CRISPR BCL11A disruption (exagamglogene autotemcel) - approved in selected markets for SCD and TDT
- High-cost, high-complexity therapies requiring specialist infusion centres
2. Access Reality #
These therapies are currently accessible to a small fraction of the global thalassemia population. Pricing (often USD multi-million per treatment), infrastructure (apheresis, myeloablative conditioning, bone-marrow transplant capability) and clinical expertise limit penetration.
3. Why Iron Chelation Still Matters #
- Patients already carrying iron burden from years of transfusion need chelation irrespective of future curative therapy - iron doesn't disappear after transplant
- Patients in low / middle-income countries will rely on conventional care for the foreseeable future
- Pre-transplant iron reduction improves transplant outcomes - chelation is part of the transplant pathway
- Chelation is simpler, safer, lower-cost and broadly available
4. Other Emerging Modalities #
- Luspatercept (activin receptor ligand trap) - reduces transfusion burden in TDT and lower-risk MDS
- Mitapivat - pyruvate kinase activator investigated in thalassemia and SCD
- Novel chelators in early-phase clinical development
5. Long View on Demand #
Even in optimistic trajectories, oral iron chelation demand is expected to grow over the coming decade - driven by expanded diagnosis, longer patient survival and extension into under-served regions.
6. Implication for Procurement #
Reliable, affordable, WHO-GMP Deferasirox supply remains a public-health priority. DEFRATAJ is supplied globally across 5 strengths. See Thalassemia page.